🔍

NATCOPHARM - Natco Pharma

📊 NSE: NATCOPHARM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 10:18

📢 Recent Corporate Announcements

Natco Pharma to Participate in Investec Promoter and Founder Conference on March 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Mar 2026, 10:23 AM

Natco Pharma Limited has scheduled an institutional investor meeting for March 9, 2026, in Mumbai. The company will be participating in the Investec Promoter and Founder Conference 2026 from 9:00 AM to 5:00 PM. The interactions are planned as in-person and group meetings with various institutional investors. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Participation in Investec Promoter and Founder Conference 2026 on March 9, 2026.
Meeting window scheduled between 9:00 AM and 5:00 PM in Mumbai.
Format includes in-person and group interactions with institutional investors.
Disclosure made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should monitor for any post-conference presentations or transcripts that may provide insights into management's outlook. No immediate action is required as this is a routine investor relations activity.

Natco Pharma Confirms Semaglutide Partnership with Eris Lifesciences for March 2026 Launch

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 25 Feb 2026, 10:02 AM

Natco Pharma has confirmed its partnership with Eris Lifesciences for the marketing of the weight-loss drug Semaglutide in India. The company received CDSCO approval for the drug on February 14, 2026, and is preparing for a commercial launch in March 2026. While the company stated the partnership is in the ordinary course of business with no immediate material financial impact, it marks a significant entry into the high-growth GLP-1 segment. Natco is currently working with multiple marketing partners to facilitate this upcoming domestic launch.

Received CDSCO approval for Semaglutide in India on February 14, 2026
Confirmed marketing partnership with Eris Lifesciences for the weight-loss drug
Product launch in the Indian market scheduled for March 2026
Company clarified that negotiations are part of ordinary business operations

💡 Investors should monitor the revenue contribution from the Semaglutide launch starting Q1 FY27, as this segment represents a major growth opportunity. The ability to scale through multiple marketing partners like Eris could provide a competitive edge in the domestic market.

Natco Pharma Proposes Reappointment of CMD and CEO with Salary Caps up to ₹1.95 Crore

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 20 Feb 2026, 01:03 PM

Natco Pharma is seeking shareholder approval via postal ballot for the reappointment of four key executive directors for a one-year term starting April 2026. The proposal includes Chairman V.C. Nannapaneni with a salary cap of ₹1.95 crore and CEO Rajeev Nannapaneni at ₹1.80 crore, both eligible for a 1% profit commission. Additionally, two other senior directors are proposed for reappointment with salaries up to ₹1.93 crore each. This move ensures leadership stability for the upcoming fiscal year while maintaining performance-linked incentives.

Proposed reappointment of CMD V.C. Nannapaneni for 1 year with ₹1.95 crore salary plus 1% profit commission
Proposed reappointment of CEO Rajeev Nannapaneni for 1 year with ₹1.80 crore salary plus 1% profit commission
Directors P.S.R.K. Prasad and Dr. D. Linga Rao proposed for 1-year terms with salaries up to ₹1.93 crore each
Shareholder e-voting period scheduled from February 23, 2026, to March 24, 2026
Remuneration includes special incentives ranging from 20% to 100% of salary depending on the role

💡 Investors should monitor the voting results to ensure leadership continuity; the short one-year tenure suggests a near-term review of leadership roles or potential succession planning.

Natco Pharma Q3 PAT at ₹151.3 Cr; Zero Revlimid Revenue; Eyes Large M&A with ₹2,500 Cr Cash

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 18 Feb 2026, 03:35 PM

Natco Pharma reported a consolidated revenue of ₹705.4 crores for Q3 FY26, showing resilience despite zero revenue contribution from Revlimid during the quarter. The company is successfully pivoting towards emerging markets like Brazil and Canada while integrating its 35.75% stake in Adcock Ingram, which is expected to contribute ₹35-40 crores to quarterly PAT. Management is actively pursuing 1-2 large acquisitions using its ₹2,500 crore cash reserve and expects GLP-1 (Semaglutide) approval for the Indian market shortly. Additionally, the de-merger of the Crop Health Sciences business is on track for completion within the next 8-9 months.

Consolidated revenue grew to ₹705.4 crores in Q3 FY26 compared to ₹651.1 crores in the previous year.
Maintained an EBITDA margin of 30.7% with a net profit of ₹151.3 crores despite zero Revlimid contribution.
Adcock Ingram acquisition expected to add approximately ₹35-40 crores to quarterly PAT moving forward.
Company holds a net cash position of ₹2,500 crores, earmarked for 1-2 large-scale acquisitions in 2026.
GLP-1 (Semaglutide) launch in India is imminent following expected DCGI approval and a fill-finish tie-up with OneSource.

💡 Investors should monitor the progress of the Crop Health de-merger and the upcoming GLP-1 launch in India as key growth catalysts. The successful transition from Revlimid dependency to a diversified emerging market model strengthens the long-term investment case.

Natco Pharma Receives CDSCO Approval for Generic Semaglutide Injection in India

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 14 Feb 2026, 09:31 AM

Natco Pharma has received regulatory approval from the CDSCO to manufacture and market generic Semaglutide injection in India. The drug is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. The company plans to launch the product in the domestic market in March 2026. This approval allows Natco to enter the high-demand GLP-1 receptor agonist segment, diversifying its portfolio beyond its traditional strength in oncology.

Received CDSCO approval to manufacture and market generic Semaglutide injection in India
Commercial launch scheduled for the Indian market in March 2026
Product targets the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise
Leverages Natco's existing infrastructure of 9 manufacturing sites and 2 R&D facilities

💡 Investors should view this as a significant portfolio expansion into the chronic care segment. Monitor the company's pricing strategy and market penetration following the March 2026 launch.

Natco Pharma Receives USFDA EIR with VAI Status for Chennai API Unit

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 13 Feb 2026, 09:18 AM

Natco Pharma has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Manali, Chennai. The inspection, which took place from November 17 to November 21, 2025, had originally resulted in seven Form-483 observations. The USFDA has now classified the inspection as Voluntary Action Indicated (VAI), meaning the facility is considered to be in a state of compliance. This resolution is a significant positive as it clears the path for future product approvals from this site.

Received Establishment Inspection Report (EIR) for the Chennai API unit from the USFDA.
The inspection conducted in November 2025 resulted in 7 observations in Form-483.
USFDA has officially classified the inspection status as Voluntary Action Indicated (VAI).
The VAI status confirms that the facility meets regulatory standards despite the initial observations.
Clears regulatory hurdles for the API division which supports the company's oncology and specialty generic portfolio.

💡 Investors should view this as a positive development that mitigates regulatory risk for Natco's API supply chain. The stock may see a positive reaction as the VAI status allows for uninterrupted business and new product approvals from the Chennai site.

Natco Pharma Releases Audio Recording of Q3 FY25-26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 06:03 PM

Natco Pharma Limited has released the audio recording of its earnings conference call for the quarter and nine months ended December 31, 2025. The call was held on February 12, 2026, following the announcement of the company's Q3 FY26 financial results. This disclosure is a standard regulatory requirement under SEBI (Listing Obligations and Disclosure Requirements) Regulations. The recording provides investors with access to management's commentary on the company's operational performance and future outlook.

Audio recording of Q3 FY25-26 earnings call made available on the company website.
The conference call was conducted on February 12, 2026, at 16:00 Hrs IST.
Filing complies with Regulation 30 and 46 of SEBI LODR Regulations, 2015.
Recording covers performance for the nine-month period ending December 31, 2025.

💡 Investors should listen to the recording to gain insights into management's commentary on product pipelines and market challenges. No immediate action is required as this is a routine administrative disclosure.

Natco Pharma Declares 3rd Interim Dividend of Rs 1.50 per Share; Record Date Feb 18

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 12 Feb 2026, 03:49 PM

Natco Pharma Limited has declared its third interim dividend of Rs 1.50 per equity share for the financial year 2025-26. This dividend represents a 75% payout on the face value of Rs 2 per share. The company has fixed February 18, 2026, as the record date to identify eligible shareholders for this payout. The distribution of the dividend is scheduled to begin on February 26, 2026.

3rd interim dividend of Rs 1.50 per equity share (75% of face value) declared for FY 2025-26
Record date for dividend eligibility is set for February 18, 2026
Dividend payment process will commence from February 26, 2026
Announcement follows the Board of Directors meeting held on February 12, 2026

💡 Investors interested in the dividend must own the shares before the ex-dividend date. Existing shareholders should verify their bank details are updated for seamless credit.

Natco Pharma Q3 PAT Up 14% YoY to ₹1,513M; Declares ₹1.50 Dividend & Chile Expansion

🔵 WATCH ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 03:48 PM

Natco Pharma reported a 14% YoY increase in consolidated net profit to ₹1,513 million for Q3 FY26, despite a significant sequential decline from Q2. The company declared a third interim dividend of ₹1.50 per share and announced the incorporation of a new subsidiary in Chile. A major milestone was the completion of the 35.75% stake acquisition in South Africa's Adcock Ingram for approximately $225 million. Additionally, the company is evaluating a demerger of its Agro Chemicals business and has appointed Amit Parekh as the new CFO.

Consolidated Revenue from operations grew 36% YoY to ₹6,473 million, though down from ₹13,630 million in Q2.
Declared third interim dividend of ₹1.50 per share (75% of face value) with record date of Feb 18, 2026.
Completed acquisition of 35.75% stake in Adcock Ingram Holdings (South Africa) for ZAR 3,873 million (~$225 million).
Approved incorporation of a wholly-owned subsidiary in Chile with an investment of up to $300,000.
Appointed Amit Parekh as CFO effective Feb 13, 2026, following the superannuation of S.V.V.N. Appa Rao.

💡 Investors should monitor the integration of the Adcock Ingram acquisition and the potential value unlocking from the proposed Agro Chemicals demerger. While YoY growth is positive, the high sequential volatility in earnings warrants a cautious approach to quarterly performance expectations.

Natco Pharma Appoints Amit Parekh as CFO and Kalakuntla Srinivas Rao as EVP Pharma Division

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 12 Feb 2026, 03:45 PM

Natco Pharma has announced a key leadership transition where Mr. Amit Parekh will take over as the Chief Financial Officer effective February 13, 2026, following the superannuation of Mr. S.V.V.N. Appa Rao. Mr. Parekh, currently an internal candidate, brings over 23 years of experience including a significant tenure at Dr. Reddy's Laboratories. Simultaneously, the company has appointed Mr. Kalakuntla Srinivas Rao as Executive Vice President of the Pharma Division, leveraging his 25+ years of experience in global regulatory compliance and operations. These appointments reflect a strategic move to bring in seasoned industry veterans to lead financial and operational functions.

Mr. Amit Parekh appointed as CFO effective February 13, 2026, succeeding Mr. S.V.V.N. Appa Rao.
Incoming CFO Amit Parekh has over 23 years of experience in finance, M&A, and digital transformation.
Mr. Kalakuntla Srinivas Rao appointed as EVP - Pharma Division effective February 12, 2026.
New EVP brings 25+ years of experience with expertise in USFDA, PMDA, and MHRA compliance.
Leadership team strengthened with former executives from Dr. Reddy's, MSN Laboratories, and Lupin.

💡 Investors should view this as a routine but important management transition; the internal promotion of the CFO suggests financial continuity while the new EVP brings valuable regulatory expertise.

Natco Pharma Appoints Amit Parekh as CFO and Kalakuntla Srinivas Rao as EVP Pharma Division

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 12 Feb 2026, 03:45 PM

Natco Pharma has announced a leadership transition following the superannuation of its current CFO, Mr. S.V.V.N. Appa Rao, effective February 12, 2026. Mr. Amit Parekh, currently EVP of Finance and Accounts with 23+ years of experience including a tenure at Dr. Reddy's, will take over as CFO on February 13, 2026. Furthermore, the company has appointed Mr. Kalakuntla Srinivas Rao as EVP of the Pharma Division, bringing over 25 years of experience from MSN Laboratories and Lupin. These moves indicate a structured succession plan and a focus on strengthening operational leadership.

Mr. S.V.V.N. Appa Rao to retire as CFO on February 12, 2026, after reaching superannuation.
Mr. Amit Parekh, with 23+ years of experience in finance and M&A, appointed as the new CFO effective February 13, 2026.
Mr. Kalakuntla Srinivas Rao appointed as EVP - Pharma Division with 25+ years of experience in USFDA and cGMP compliance.
New CFO Amit Parekh previously held senior finance roles at Dr. Reddy’s Laboratories and has expertise in IFRS and US GAAP.
EVP Kalakuntla Srinivas Rao has a proven track record in managing formulation operations and facility design.

💡 This is a planned leadership transition and should be viewed as a routine corporate development. Investors should monitor if the new leadership introduces any shifts in financial strategy or operational focus in the coming years.

Natco Pharma Q3 FY26 Net Profit Rises 14% to INR 1,513 Mn; Revenue Up 8% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 03:02 PM

Natco Pharma reported a consolidated revenue of INR 7,054 Mn for Q3 FY26, an 8.3% increase over the previous year. Net profit grew 14.3% YoY to INR 1,513 Mn, aided by the strategic acquisition of a 35.75% stake in South Africa's Adcock Ingram. Export formulations continue to be the backbone of the business, contributing nearly 76% of the quarterly revenue. The company is also advancing its pipeline with 30 approved Para IVs and significant R&D investments in cell and gene therapy.

Q3 FY26 Revenue reached INR 7,054 Mn compared to INR 6,511 Mn in Q3 FY25.
Net Profit stood at INR 1,513 Mn with an EPS of INR 8.46 for the quarter.
Export Formulations revenue grew to INR 4,214 Mn, representing 75.7% of total revenue.
Integration of Adcock Ingram (South Africa) contributed INR 109 Mn to the bottom line after amortization.
Robust pipeline includes 14 Solo FTFs and 30 approved Para IV products for the US market.

💡 Investors should maintain a positive outlook given the strong 9-month performance (EPS of INR 64.24) and the potential of the US pipeline. Monitor the scaling of the Crop Health Sciences segment and the long-term impact of the South African acquisition.

Natco Pharma Q3 Net Profit Rises 14% YoY to ₹151 Cr; Declares ₹1.50 Interim Dividend

🔵 WATCH ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 02:40 PM

Natco Pharma reported a consolidated net profit of ₹1,513 million for Q3 FY26, marking a 14.3% growth year-on-year, though profits declined sharply on a sequential basis from ₹5,179 million in Q2. The company declared its third interim dividend of ₹1.50 per share for the fiscal year. Strategically, Natco completed a significant 35.75% stake acquisition in South Africa's Adcock Ingram for approximately $225 million and announced a new subsidiary in Chile. Management changes include the appointment of Amit Parekh as the new CFO following the retirement of S.V.V.N. Appa Rao.

Consolidated Revenue from operations grew 36.3% YoY to ₹6,473 million in Q3 FY26.
Declared 3rd interim dividend of ₹1.50 per share (75% on face value of ₹2) with record date Feb 18, 2026.
Completed $225 million acquisition of 35.75% stake in Adcock Ingram Holdings, South Africa.
Board approved the incorporation of a wholly owned subsidiary in Chile with $300,000 investment.
Amit Parekh appointed as CFO effective Feb 13, 2026, succeeding the retiring S.V.V.N. Appa Rao.

💡 Investors should focus on the successful integration of the Adcock Ingram acquisition and the potential value unlocking from the proposed Agro Chemicals demerger. While YoY growth is positive, the inherent quarterly volatility in Natco's earnings due to product-specific profit sharing requires a long-term investment horizon.

Natco Pharma Declares ₹1.50 Dividend; Q3 Net Profit Rises 14% YoY to ₹1,513 Million

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 02:32 PM

Natco Pharma reported a steady performance for Q3 FY26, with consolidated revenue growing 36% YoY to ₹6,473 million. Net profit increased by 14% YoY to ₹1,513 million, supported by a ₹109 million contribution from its new South African associate, Adcock Ingram. The company declared its third interim dividend of ₹1.50 per share and announced the appointment of Amit Parekh as the new CFO. Strategic moves include a new subsidiary in Chile and the ongoing evaluation of a demerger for the Agro Chemicals business.

Declared third interim dividend of ₹1.50 per equity share (75% of face value) with a record date of Feb 18, 2026.
Consolidated Revenue from operations rose to ₹6,473 million in Q3 FY26 from ₹4,748 million in Q3 FY25.
Net Profit for the quarter stood at ₹1,513 million compared to ₹1,324 million in the same period last year.
Completed acquisition of 35.75% stake in Adcock Ingram Holdings (South Africa) for ZAR 3,873 million (~$225 million).
Board approved the incorporation of a new wholly-owned subsidiary in Chile with an investment of up to $300,000.

💡 Investors should monitor the integration of the Adcock Ingram acquisition and updates regarding the potential demerger of the Agro Chemicals segment. The steady dividend payout and international expansion remain positive indicators for long-term holders.

Natco Pharma Receives Tentative US FDA Approval for Generic Balversa; $60M Market Opportunity

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 03 Feb 2026, 02:50 PM

Natco Pharma has received tentative approval from the U.S. FDA for Erdafitinib tablets, which is a generic version of Janssen Biotech's Balversa. The drug is used to treat adult patients with specific types of metastatic urothelial carcinoma. For the 12-month period ending September 2025, the reference drug had estimated sales of approximately $60 million in the U.S. market. This development is consistent with Natco's strategy of focusing on niche oncology products with limited competition in the United States.

Received tentative U.S. FDA approval for Erdafitinib tablets in 3mg, 4mg, and 5mg strengths.
Generic version of Balversa, targeting locally advanced or metastatic urothelial carcinoma.
Reference drug annual U.S. sales estimated at $60 million as of September 2025.
Strengthens Natco's position as a leading oncology player in the U.S. generics market.

💡 Investors should view this as a positive addition to Natco's U.S. pipeline, though the immediate financial impact is limited by the 'tentative' nature of the approval. Monitor for the transition to final approval and the subsequent commercial launch timeline.

View All NATCOPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total consolidated revenue grew 15.9% YoY to INR 4,784 Cr in FY25 from INR 4,126.9 Cr in FY24. The Pharmaceutical segment remains the primary driver, while the Crop Health Sciences (Agrochemicals) segment contributed INR 59.8 Cr in FY25, a decline from INR 108.3 Cr in FY24. Q2 FY26 revenue stood at INR 1,463 Cr, a marginal 1.9% increase over Q2 FY25.

Geographic Revenue Split

The company exports to over 50 countries. Key markets include the US (driven by gRevlimid profit sharing), India (domestic oncology), and emerging markets like Brazil and Canada which showed healthy growth. New product filings have commenced in Latin America, with expansion planned for Saudi Arabia, Algeria, Morocco, and Egypt.

Profitability Margins

Operating Profit Margin (OPM) improved to 49.6% in FY25 from 43.9% in FY24. However, margins contracted to 42.7% in H1 FY26 due to pricing pressures in the US and domestic markets and higher R&D provisions. PAT margin stood at 39.4% in FY25 compared to 33.6% in FY24.

EBITDA Margin

EBITDA margin was 53.3% in FY25, up from 45.5% in FY24. For Q2 FY26, the EBITDA margin was reported at 46.4% with an absolute EBITDA of INR 679.2 Cr, reflecting a moderation from FY25 peaks as the gRevlimid patent expiry approaches.

Capital Expenditure

The company has planned a total capex of INR 800 Cr for FY26 and FY27 combined. This includes maintenance and expansion capex of approximately INR 250-300 Cr per annum to support new product launches and capacity optimization.

Credit Rating & Borrowing

Maintains a robust financial profile with a TD/OPBITDA of 0.1 times as of September 2025. Interest coverage was exceptionally high at 91.9 times in FY25. The company has a negative net debt position with cash reserves of approximately INR 3,200 Cr as of September 30, 2025.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) for oncology, diabetic, and anti-infective segments. The company is backward-integrated for several key formulations, though specific chemical names and their % of total cost are not disclosed.

Import Sources

Not specifically disclosed, but the company operates with a global supply chain to mitigate risks for high-lead-time products.

Capacity Expansion

Current capacity is not disclosed in MT/units, but the company is expanding its presence in emerging markets and agrochemicals. Capex of INR 800 Cr is earmarked for FY26-27 to support this expansion.

Raw Material Costs

Raw material costs are managed through backward integration in APIs. The company maintains high inventory levels (193 days in Sept 2025) to mitigate supply chain challenges for high-value products.

Manufacturing Efficiency

The company focuses on optimizing production schedules to minimize switchover costs at plants that manufacture multiple APIs or formulations.

Logistics & Distribution

Not disclosed as a specific % of revenue, but international expansion into Brazil, Canada, and China has led to higher receivables periods.

📈 Strategic Growth

Expected Growth Rate

10-15%

Growth Strategy

Growth will be driven by the launch of Semaglutide (March 2026), expansion into the MENA region (Saudi Arabia, Egypt), and the INR 2,000 Cr acquisition of a stake in AIHL in November 2025. The company is also focusing on niche Para IV filings and diversifying into Agrochemicals.

Products & Services

Oncology formulations, gRevlimid (Lenalidomide), Semaglutide (diabetic segment), anti-infectives, APIs, and Agrochemical products (Crop Health Sciences).

Brand Portfolio

Natco, gRevlimid (generic version).

New Products/Services

Planned launch of Semaglutide 2.4 MG injection in March 2026. New launches in oncology, diabetic, and anti-infective segments are expected to offset pricing pressures.

Market Expansion

Targeting expansion in Saudi Arabia, Algeria, Morocco, and Egypt. Increasing focus on Brazil, Canada, Southeast Asia, and China.

Market Share & Ranking

Leading player in the domestic oncology segment in India.

Strategic Alliances

Strategic partnerships are used for global expansion and niche molecule development; specific partner names for recent JVs were not disclosed.

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and specialty medicines. Natco is positioning itself by moving into peptides (Semaglutide) and agrochemicals to diversify away from pure generic pricing wars.

Competitive Landscape

Key competitors include Novo Nordisk and Emcure (specifically in the Semaglutide market). The US market remains highly competitive with intense pricing pressure.

Competitive Moat

Moat is built on strong R&D capabilities in complex generics and backward integration in APIs. This is sustainable due to high entry barriers in oncology and complex molecules, though patent expiries (gRevlimid) pose a recurring challenge.

Macro Economic Sensitivity

Sensitive to healthcare regulatory changes and inflationary pressures which impacted OPM in 9M FY25.

Consumer Behavior

Shift toward affordable complex generics in emerging markets and increasing demand for diabetic treatments (GLP-1 analogues).

Geopolitical Risks

Exposure to trade barriers and regulatory scrutiny in 50+ export countries, including potential impacts from US-China trade dynamics affecting API sourcing.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA inspections, cGMP compliance, and price controls in the domestic Indian market. Regulatory scrutiny and compliance costs are noted as increasing risks.

Environmental Compliance

Not disclosed in absolute INR values, but the company adheres to cGMP norms and high-quality standards.

Legal Contingencies

The company is involved in Para IV patent litigations in the US. While specific case values are not disclosed, these litigations are critical for maintaining the exclusivity of products like gRevlimid.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the extent of revenue moderation following the gRevlimid patent expiry in Q2 FY26. Regulatory risks from USFDA audits could impact export capabilities.